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In order to evaluate the pharmacokinetic profile of paliperidone extended-release tablets
in vivo, a simple and rapid ultra-high performance liquid chromatographyetandem mass
spectrometry (UHPLCeMS/MS) method was developed and validated for the determination
of paliperidone in beagle dog plasma. Paliperidone and diazepam (internal standard) were
extracted from plasma samples with diethyl ether, and then separated on a C18 column
(2.1  50 mm, 2.6 mm) under gradient elution with methanole0.1% formic acid at a flow rate
of 0.3 ml/min. The compounds were detected using a triple-quadrupole mass spectrometer
equipped with an electrospray ionization (ESI) source. The validated method was linear
over the concentration range of 1.00e1000.00 ng/ml and the lower limit of quantitation was
1.00 ng/ml. The intra-day and inter-day precision values were not more than 15% (relative
standard deviation < 20% at low levels), while the accuracy was within ±10% of nominal
values. The validated UHPLCeMS/MS method was successfully applied to an oral phar-
macokinetic study of paliperidone extended-release tablets in a beagle dog.
© 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Risperidone is a second-generation antipsychotic agent
widely used in the treatment of schizophrenia. It is converted; fax: þ86 24 23986321.
(T. Zhang).
g Pharmaceutical Univer
University. Production anto the active metabolite, paliperidone, in vivo. In fact, the
“active fraction” during risperidone treatment is considered to
be the sum of risperidone and paliperidone [1e3].
Among neurological diseases, schizophrenia is a long-term
recurrent and chronic disease which requires a long-termsity.
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a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 2 8 6e2 9 2 287treatment with antipsychotic agents [4,5]. However, after
long-term continuous medication with routine medicines, a
lot of adverse reactions, poor drug tolerance and compliance
may occur. In the light of these problems, an osmotic-
controlled release oral delivery system (OROS) has been used
to prepare paliperidone extended-release tablets. This results
in relatively stable and effective plasma concentrations over
24 h, which permits once a day dosing and treatment using a
potentially effective dose, to reduce any negative side effects
and improve patient compliance and tolerance [6e8].
Earlier publications have described methods for simulta-
neous determination of paliperidone and risperidone in a
biological matrix using high performance liquid chromatog-
raphy (HPLC) methods with ultraviolet detection (UV) or
electrochemical detection [9e13], and liquid chromatogra-
phyetandemmass spectrometry (LC-MS/MS) methods [14,15].
However, these methods are not suitable for the determina-
tion of paliperidone alone because of the long run time and/or
complicated sample processing procedures. Several methods
for the determination of paliperidone together with a variety
of other drugs and metabolites in biological samples have
been published using LC-MS/MS methods [16,17]. However,
using protein precipitation (PPT), the samples are dirty and
cause damage to the chromatographic column and mass
spectrometry system.
To date, some publications for the determination of pal-
iperidone alone in biological fluids have been reported. Xu
et al. [18] reported amethod involving liquideliquid extraction
(LLE)-HPLC with UV-detection but this required large volumes
of biological samples and the sample processing was
complicated. Vermeir et al. [19] developed an LC-MS/MS
method for the determination of paliperidone in human
plasma, which achieved a better sensitivity and the chro-
matographic separation time was about 6 min. However, as
far as sample preparation was concerned, it used a solid-
phase extraction (SPE) method which was complex and
expensive.
In this paper, we attempted to develop a simple and rapid
method for the determination of paliperidone in beagle
plasma using a UHPLCeMS/MS method to evaluate the oral
pharmacokinetics of paliperidone extended-release tablets.
Compared with previous methods, the present method had
the following advantages: less plasma was required, sample
preparation was simpler, and the analysis time was shorter.
The lower limit of quantitation (LLOQ) was 1 ng/ml with LLE
using 200 ml plasma, which was sensitive enough to measure
the low concentrations of paliperidone in beagle plasma.
Moreover, the analysis time for a single sample was 3 min.
Finally, the method was successfully applied to evaluate the
pharmacokinetic characteristics after oral administration of
paliperidone to a beagle dog.2. Materials and methods
2.1. Materials
Paliperidone (99.82% purity) was provided by a laboratory in
Shenyang Pharmaceutical University, and its structure was
validated by comparison with chemical and spectroscopic(UV, MS and NMR) data, and its purity was measured by the
area normalization method. Diazepam (purity > 99.0%) was
purchased from the Zhejiang Xinhua Pharmaceutical Co. Ltd
(Zhejiang, China). Methanol (HPLC grade) was purchased from
Fisher Scientific (Pittsburgh, PA, USA). Formic acid (HPLC
grade) was obtained from Dikma Reagent Company (Ohio,
USA). Diethyl ether was purchased from Concord Chemical
(Shenyang, China). Paliperidone extended-release tablets
were prepared in the laboratory (3 mg).2.2. Instrumentation
Chromatographywas performed on aWaters ACQUITY™ TQD
system, which consisted of an ACQUITY™ Ultra Performance
Liquid Chromatography system coupled to an ACQUITY™
triple-quadrupole tandem mass spectrometer with an elec-
trospray ionization (ESI) interface (Waters Corp., Milford, MA,
USA). A phenomenex C18 column (2.1  50 mm, 2.6 mm; Phe-
nomenex Co., USA) was used to separate the analytes.2.3. UHPLC-MS-MS conditions
Gradient elution was conducted for chromatographic sepa-
ration with methanol as mobile phase A and 0.1% formic acid
as themobile phase B. At a flow rate of 0.3ml/min, the amount
of eluent A was increased linearly from 20% to 80% over
1.5 min, then held at 80% for 1 min and returned to the initial
conditions and re-equilibration took place for another 0.5min.
This resulted in a total run time of 3 min per sample. The
column and auto-sampler temperature was 40 C and 4 C,
respectively and the sample volume injected was 5 ml.
Regarding MS detection, the ESI was operated in positive
mode. The capillary voltage was 3.8 kV and the cone voltage
was 35 V for both paliperidone and diazepam; the collision
energy of paliperidone and diazepam was 28 and 23 V,
respectively; nitrogen was used as the desolvation and cone
gas at 500 L/h and 50 L/h, respectively; the source temperature
was 120 C and the desolvation temperature was 350 C.
Quantification was performed in multiple-reaction moni-
toring (MRM) mode of the transitions m/z 427.31/ 207.18 for
paliperidone and m/z 285.12/ 193.13 for diazepam. The full-
scan product ion spectra of paliperidone and diazepam are
shown in Fig. 1.2.4. Preparation of standards and quality control (QC)
samples
Stock solutions of paliperidone (1 mg/ml) and diazepam
(0.1 mg/ml) were separately prepared in methanol. The stock
solution of paliperidone was further diluted with methanol to
obtain working solutions for the preparation of calibration
standards. All solutions were stored at 4 C and were brought
to room temperature before use.
The diazepam solution was further diluted with methanol
to 500.00 ng/ml. Calibration standard samples were prepared
by spiking 200 ml samples of blank beagle plasma with 50 ml
paliperidone working standard solutions. The final concen-
trations in standard plasma samples were 1.00, 2.00, 10.00,
50.00, 100.00, 500.00, and 1000.00 ng/ml. The QC samples were
Fig. 1 e Full-scan positive mode product ion mass spectrum of (A) paliperidone and (B) diazepam.
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centrations of 2.00, 50.00 and 800 ng/ml.
2.5. Plasma sample preparation
Plasma (200 ml), 50 ml diazepam solution (500 ng/ml) and 50 ml
methanol were added to 10.0 ml screw-capped tubes. After
briefly vortexing for 1 min, 2 ml diethyl ether was added andthe mixture was vortexed for another 3 min. This was fol-
lowed by centrifugation at 3500 rpm for 10min, then the upper
organic layer was transferred to another 10.0 ml centrifuge
tube and evaporated to dryness under a nitrogen stream at
37 C. The residue was then reconstituted with 100 ml
methanol-water (80:20, v/v). After centrifugation at 13,000 rpm
for 10 min, 5 ml aliquots were injected into the UHPLCeMS/MS
system for analysis.
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Selectivitywas investigated by comparing the chromatograms
of blank beagle plasma with the corresponding spiked beagle
plasma. Linearity was assessed by weighted (1/x2) linear
regression analysis of the paliperidone/diazepam peak area
ratio versus the nominal concentration (x) of paliperidone in
plasma. LLOQ was used to define the sensitivity with the
concentration of 1.00 ng/ml, with an acceptable accuracy be-
tween 80% and 120% and a precision with a deviation not
exceeding 20%. The intra-and inter-day precision and accu-
racy were determined by analysis of six replicates at low,
middle, and high QC levels on the same day and three batches
on three different days. The matrix effect was investigated by
comparing the peak areas of the post-extracted blank plasma
with those of the corresponding standard solutions. The
extraction recovery was evaluated by comparing the re-
sponses of six replicates of extracted QC samples with the
mean peak area response of those samples extracted before
adding paliperidone and diazepam at three QC levels. The
stability of low, middle and high QC samples (n ¼ 3) was
measured under different conditions: freezeethaw stability
(20 C to ambient temperature), post-preparation stability
(kept in an auto-sampler at 4 C for about 12 h), short-term
stability (ambient temperature for 12 h) and long-term sta-
bility (20 C for 40 days).2.7. Application to a pharmacokinetic study
After a 24 h fast, a healthy dog was given two paliperidone
extended-release tablets (6 mg). All animal experiments were
performed in accordance with the institutional guidelines
and approved by the Shenyang Pharmaceutical University
Animal Care and Use Committee .The blood samples (5 ml)
were collected in heparinized plastic tubes at 0, 2, 4, 8, 12, 16,
18, 20, 22, 24, 26, 30, 32, 36, 48, 60, and 72 h, respectively.
Following centrifugation at 13,000 rpm for 10 min, the
plasma samples were separated and stored at 20 C until
analysis.3. Results and discussion
3.1. Method development
Gradient elution was applied to shorten the run time. Using
methanol as eluent A, and formic acid (0.1%) as eluent B,
eluent A was increased linearly from 20% to 80% over the first
1.5 min, followed by a 1 min hold at 80%. Formic acid (0.1%) is
important because it improves the peak shape.
LLE, SPE and protein precipitation (PPT) are themostwidely
used methods for sample preparation. Although the matrix
effect and recovery of SPE are adequate, the method is
complicated and expensive. Although PPT is rapid and simple
to perform, the method resulted in a strong matrix effect. LLE
was examined to obtain cleaner samples. In this experiment,
diethyl ether and methyl tert-butyl ether were examined as
the extraction solvent. Methyl tert-butyl ether exhibited a
strong matrix effect. Finally, diethyl ether was selected as theextraction solvent because it produced a higher recovery and
lower matrix effect.
3.2. Method validation
3.2.1. Selectivity
Selectivity was assessed by comparing the chromatograms
of blank plasma, standard solution (1.00 ng/ml), blank
plasma spiked with paliperidone (1.00 ng/ml) and a diaz-
epam and plasma sample about 18 h after oral administra-
tion of paliperidone. As shown in Fig. 2, there was no
interference with paliperidone and diazepam in the blank
plasma samples.
3.2.2. Linearity and sensitivity
The calibration curves exhibited excellent linearity with
regression correlation coefficients (r2 > 0.99) over the con-
centration range of 1.00e1000.00 ng/ml in dog plasma. A
typical regression equation was: y ¼ 8.77x þ 7.51 with a
determination coefficient (r2) of 0.9960. The LLOQ was 1.00 ng/
ml for paliperidone, the precision was 13% of the relative
standard deviation (RSD) and the accuracy was 11% of the
relative error (RE).
3.2.3. Precision and accuracy
The intra-day and inter-day precision and accuracy for
paliperidone are summarized in Table 1.The intra-day and
inter-day precisions were all below 15% (RSD < 20% at low
levels) and the maximum deviation in accuracy was below
10%.
3.2.4. Extraction recovery and matrix effect
The extraction recoveries from beagle dog plasma were
excellent for paliperidone: 92.10 ± 2.99%, 87.83 ± 1.60%,
92.25 ± 1.81% for the low, middle and high QC levels, respec-
tively, and the extraction recovery of diazepam was
90.22 ± 2.10%.
In our experiment, all the ratios of the matrix effect eval-
uated were between 88.47% and 95.64%, which indicated that
the endogenous substances had no significant effect on the
two study compounds.
3.2.5. Stability
The stability of paliperidone in dog plasma was investigated
under a variety of storage and process conditions, which are
summarized in Table 2. The results indicated that paliper-
idone was stable under the conditions described.
3.3. Pharmacokinetic application
The validated method was successfully applied to the phar-
macokinetic study of paliperidone following oral administra-
tion of paliperidone extended-release tablets to a beagle dog.
The plasma concentrationetime profile of paliperidone is
illustrated in Fig. 3. The pharmacokinetic data indicated that
paliperidone reached a peak concentration in plasma about
18 h after oral administration and paliperidone could still be
quantified in plasma 72 h after oral administration. The
application to the pharmacokinetic study of paliperidone
indicated that this analytical method was suitable and
Fig. 2 e MRM chromatograms of paliperidone and diazepam from (A) a blank plasma sample; (B) standard solution sample
(1.00 ng/ml); (C) a plasma sample with added paliperidone and diazepam at the LLOQ level; (D) a plasma sample from a dog
following oral administration of paliperidone (6 mg).
Fig. 3 e Concentrationetime profile of paliperidone in
beagle plasma after a single oral dose of 6 mg paliperidone
extended-release tablets (n ¼ 1).
Table 2 e Stability of paliperidone in dog plasma under
indicated conditions (mean ± SD, n ¼ 3).
Conditions Add
(ng/ml)
Found
(ng/ml)
RSD%
Post-preparation stability 2.00 2.11 ± 0.34 16
50.00 44.52 ± 1.22 2.7
800.00 792.90 ± 28.90 3.6
2.00 2.28 ± 0.11 4.8
Short-term stability 50.00 52.13 ± 1.19 2.3
800.00 725.28 ± 17.88 2.5
2.00 2.10 ± 0.19 9
Freezeethaw stability 50.00 43.07 ± 0.30 0.70
800.00 815.17 ± 15.28 1.9
2.00 1.78 ± 0.17 10
Long-term stability 50.00 43.26 ± 0.88 2.0
800.00 808.61 ± 58.18 7.2
Table 1 e Precision and accuracy data for assay of
paliperidone (intra-day: n ¼ 6; inter-day: n ¼ 6 series per
day, 3 days).
Added
(ng/ml)
Found
(ng/ml)
Intra-day
RSD (%)
Inter-day
RSD (%)
Accuracy
RE (%)
2.00 1.99 ± 0.16 6.7 15 0.50
50.00 45.39 ± 1.70 3.9 2.4 9
800.00 794.94 ± 19.10 2.4 2.1 0.63
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plasma.4. Conclusion
This paper describes a rapid, sensitive and specific
UHPLCeMS/MS method developed for the quantification of
paliperidone and its validation for the analysis of paliperidone
in beagle plasma. The UHPLCeMS/MS method has significant
advantages over other techniques including the simplicity of
sample preparation; sharper peaks and a higher extraction
recovery and a shorter chromatographic run time. The
method has been successfully applied to the pharmacokinetic
study of paliperidone in dog plasma samples.r e f e r e n c e s
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